The overall objective of this program is to support a multicenter case- control study on the potential etiologic factors for sarcoidosis. Cases will also be followed to gain information on the natural history of this disease including risk factors for progression of disease. A steering committee will develop a protocol and manual of operations which will address the most promising hypotheses to be pursued to identify the cause(s) of sarcoidosis. The protocol will include a comprehensive clinical characterization of each participant and determination of markers of immune responsiveness. The contractor will participate in a system for banking biological specimens. A clinical coordinating center will be established to collect, manage and analyze the data from the clinical centers. It is estimated that the total study population will consist of 720 cases and 1,440 controls. It is estimated that each clinical center will enroll, interview, and examine 72 cases (age 21 years or older) with sarcoidosis and, enroll, interview and collect a blood specimen from 144 matched control subjects over a four year period. Clinical centers will 1) test specific hypotheses involving risk factors, familial aggregation, and genetics of the etiology of this disease and 2) describe the natural history of sarcoidosis. A six year schedule is envisioned as follows: Phase I (12 Months): A collaborative protocol and manual of operations will be developed; Phase II (48 Months): will involve the recruitment and follow-up of patients and recruitment and interviewing of control subjects, and Phase III (12 Months): will involve data analysis.
| McDougal, Kathryn E; Fallin, M Daniele; Moller, David R et al. (2009) Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. J Invest Dermatol 129:1921-6 |
| Rossman, M D; Thompson, B; Frederick, M et al. (2008) HLA and environmental interactions in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 25:125-32 |
| Wasfi, Y S; Silveira, L J; Jonth, A et al. (2008) Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African-Americans. Tissue Antigens 72:39-48 |
| Zheng, Gang; Tian, Xin; ACCESS Research Group (2006) Robust trend tests for genetic association using matched case-control design. Stat Med 25:3160-73 |
| Baughman, R P; Judson, M A; Teirstein, A et al. (2006) Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 99:307-15 |
| Kreider, Mary Elizabeth; Christie, Jason D; Thompson, Bruce et al. (2005) Relationship of environmental exposures to the clinical phenotype of sarcoidosis. Chest 128:207-15 |
| Barnard, Juliana; Rose, Cecile; Newman, Lee et al. (2005) Job and industry classifications associated with sarcoidosis in A Case-Control Etiologic Study of Sarcoidosis (ACCESS). J Occup Environ Med 47:226-34 |
| Rybicki, Benjamin A; Walewski, Jose L; Maliarik, Mary J et al. (2005) The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 77:491-9 |
| Yeager, Henry; Rossman, Milton D; Baughman, Robert P et al. (2005) Pulmonary and psychosocial findings at enrollment in the ACCESS study. Sarcoidosis Vasc Diffuse Lung Dis 22:147-53 |
| Newman, Lee S; Rose, Cecile S; Bresnitz, Eddy A et al. (2004) A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med 170:1324-30 |
Showing the most recent 10 out of 16 publications
